Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.
This is a video synopsis/summary of a Precision Medicine series featuring Hana Safah, MD, and Jamie Koprivnikar, MD.
Drs Safah and Koprivnikar outline eligibility criteria for allogeneic stem cell transplant referral in myelodysplastic syndrome (MDS), still relying predominantly on Revised International Prognostic Scoring System (IPSS-R) risk stratification. Candidates are typically higher risk, now defined as intermediate-2 or high by IPSS-R. Debate remains regarding very high-risk disease.
Equally important is assessing patient fitness, not just age, via the hematopoietic cell transplantation–specific comorbidity index given the elder MDS population. The goal is to select those most likely to benefit and tolerate intense therapy to achieve potential cure rather than undue toxicity.
Exceptions may include lower-risk MDS with very heavy transfusion dependence or adverse molecular features unresponsive to other treatments. Careful patient selection allows optimal application of this potentially curative modality only available to appropriately fit candidates.
Ongoing reevaluation of evolving criteria should further enhance appropriate utilization moving forward.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
FDA Clears Phase 1 Study of Lomonitinib for R/R AML Treatment in the US
June 10th 2024An investigational new drug application for lomonitinib has been cleared by the FDA for FLT3-mutated relapsed/refractory AML treatment, and a phase 1 trial evaluating the agent will begin in the US.
Read More
How to Handle CLS From Tagraxofusp and Maintain Treatment in BPDCN
June 5th 2024During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses the adverse events, like capillary leak syndrome, that come with the use of tagraxofusp when treating patients with blastic plasmacytoid dendritic cell neoplasm in the second article of a 2-part series.
Read More